SCHEMBL228245

SCHEMBL228245

COc1ccc(C2Cc3cc(OC)cc(O)c3C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 3/20 0.53
ALOX15 P16050 2/20 0.53
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
KDM1A O60341 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
CYP1A1 P04798 3/20 0.40
CYP1B1 Q16678 3/20 0.40
CYP1A2 P05177 2/20 0.40
LDHA P00338 1/20 0.40
LDHB P07195 1/20 0.40
CYP3A4 P08684 2/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL224561 0.87 ALOX12 (0.47) ALOX12ALOX15KMT2AMAPTKDM1A
SCHEMBL4453886 0.83 ALOX15 (0.45) ALOX12ALOX15KMT2AMAPTKDM1A
SCHEMBL9187057 0.75 DRD1 (0.48) ALOX12ALOX15KMT2AALDH1A1MAPK1
SCHEMBL224746 0.72 CYP26A1 (0.43) ALOX12ALOX15KMT2AMAPTMAPK1
SCHEMBL226782 0.72 DRD2 (0.40) ALOX12ALOX15KMT2AMAPTALDH1A1
SCHEMBL19428987 0.71 CYP26A1 (0.52) ALOX12ALOX15KMT2AMAPTALDH1A1
SCHEMBL10562731 0.70 ALOX15 (1.00) ALOX12ALOX15KMT2AKDM1APOLB
SCHEMBL11714105 0.70 ESR2 (0.57) ALOX12ALOX15KMT2AMAPTKDM1A
SCHEMBL38662450 0.69 ESR1 (0.76) ALOX12ALOX15KMT2AMAPTALDH1A1
SCHEMBL12914761 0.69 ESR1 (0.76) ALOX12ALOX15KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1577288-B1 Selective estrogen receptor modulators EISAI R&D MAN CO LTD (JP) 2014-07-23 EP disclosed
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 US disclosed
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 US disclosed
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 ALOX12 3509/4885ALOX15 3373/4885KMT2A 371/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 ALOX12 3690/4885ALOX15 3730/4885KMT2A 216/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 ALOX12 3279/4885ALOX15 2978/4885KMT2A 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.